Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company whose news flow centers on cardiometabolic and neurological drug development, regulatory interactions and strategic collaborations. The company describes a mission of pioneering medicines that transform patients’ lives, supported by its Genome5000™ genomics platform, which identified more than 100 protein targets with therapeutic potential across multiple diseases.
News about Lexicon frequently highlights clinical data and conference presentations for sotagliflozin, an oral SGLT2 and SGLT1 inhibitor studied in approximately 20,000 patients with heart failure, diabetes and chronic kidney disease. Recent updates include results in heart failure with preserved ejection fraction, ongoing enrollment in the SONATA-HCM Phase 3 study for hypertrophic cardiomyopathy, and work toward regulatory pathways for ZYNQUISTA® in type 1 diabetes.
Investors and healthcare observers can also follow developments in pilavapadin (LX9211) for diabetic peripheral neuropathic pain, where Lexicon has reported Phase 2 and Phase 2b data and End-of-Phase 2 FDA discussions, as well as LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders licensed to Novo Nordisk. Company news includes licensing milestones, financial results, participation in major healthcare conferences and policy-focused initiatives such as a chronic pain roundtable and white paper on non-opioid treatments.
This LXRX news page aggregates these updates in one place, covering earnings releases, pipeline milestones, regulatory announcements, scientific publications and partnership news drawn from Lexicon’s public statements and SEC filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the acceptance of data from its Phase 2 trial, RELIEF-PHN-1, for investigational drug LX9211 in treating postherpetic neuralgia (PHN) at the AAN Annual Meeting in Boston.
The trial results will be presented on April 24, 2023. Previous data from December 2022 indicated LX9211's potential as an effective non-opioid treatment for neuropathic pain, following positive results from another trial, RELIEF-DPN-1, demonstrating significant pain reduction.
LX9211 targets neuropathic pain via AAK1 inhibition and has Fast Track designation from the FDA for diabetic peripheral neuropathic pain. Overall, the company aims to develop innovative medicines to transform patient care.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
